AQR Capital Management
RPTX

AQR Capital Management’s Repare Therapeutics RPTX Stock Holding History

AQR Capital Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-31,126
Closed -$306K – 2267
2023
Q1 		$306K Buy
31,126
+13,319
+75% +$153K ﹤0.01% 1943
2022
Q4 		$262K Buy
+17,807
New +$266K ﹤0.01% 2008

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

AQR Capital Management's RPTX Position: Q2 2023 in Review

AQR Capital Management sold out of Repare Therapeutics (RPTX) in Q2 2023, closing a stake of 31,126 shares — an estimated $306K sold.

AQR Capital Management first reported a position in RPTX in Q4 2022 and held it in 2 quarters. The position peaked at $306K in Q1 2023. 78 funds tracked by Wall St. Rank hold RPTX as of Q2 2023.

  • AQR Capital Management reported no remaining Repare Therapeutics position as of Q2 2023 after selling out during the quarter.
  • AQR Capital Management sold 31,126 Repare Therapeutics shares in Q2 2023, an estimated $306K.
  • AQR Capital Management first reported a position in Repare Therapeutics in Q4 2022 and held it in 2 quarters.
  • AQR Capital Management's Repare Therapeutics position peaked at $306K in Q1 2023.
  • 78 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2023.

Based on AQR Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.